Cumulative retention rate of adalimumab in patients with Behçet's disease-related uveitis: A four-year follow-up study

C. Fabiani, J. Sota, A. Vitale, D. Rigante, G. Emmi, L. Vannozzi, D. Bacherini, G. Lopalco, S. Guerriero, S. Gentileschi, M. Capozzoli, R. Franceschini, B. Frediani, M. Galeazzi, F. Iannone, G.M. Tosi, L. Cantarini

Research output: Contribution to journalArticle

Abstract

Background/aims Adalimumab (ADA) has been shown to be an effective treatment for Behçet's disease (BD)-related uveitis. We aimed at evaluating the cumulative retention rate of ADA during a 48-month follow-up period in patients with BD-related uveitis, the impact of a concomitant use of disease modifying anti-rheumatic drugs (DMARDs) on ADA retention rate, and differences according to the various lines of biologic therapy (ie, first- vs second-line or more). Predictive factors of response to ADA were also investigated. Methods We enrolled patients diagnosed with BD-related uveitis and treated with ADA between January 2009 and December 2016. Cumulative survival rates were studied using the Kaplan-Meier plot, while the log-rank (Mantel-Cox) test was used to compare survival curves. Statistical analysis was performed to identify differences according to the response to ADA. Results 54 consecutive patients (82 eyes) were eligible for analysis. The drug retention rate at 12- and 48-month follow-up was 76.9% and 63.5%, respectively. No statistically significant differences were identified according to the use of concomitant DMARDs (p=0.27) and to the different lines of ADA treatment (p=0.37). No significant differences were found between patients continuing and discontinuing ADA in terms of age (p=0.24), age at BD onset (p=0.81), age at uveitis onset (p=0.56), overall BD duration (p=0.055), uveitis duration (p=0.46), human leucocyte antigen-B51 positivity (p=0.51), and gender (p=0.47). Conclusions ADA retention rate in BD-related uveitis is excellent and is not affected by the concomitant use of DMARDs or by the different lines of biological therapy. Negative prognostic factors for BD uveitis do not impact ADA efficacy. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved.
Original languageEnglish
Pages (from-to)637-641
Number of pages5
JournalBritish Journal of Ophthalmology
Volume102
Issue number5
DOIs
Publication statusPublished - 2018

Fingerprint

Uveitis
Antirheumatic Agents
Biological Therapy
Adalimumab
HLA Antigens
Age of Onset
Survival Rate
Survival

Keywords

  • adalimumab
  • dexamethasone
  • disease modifying antirheumatic drug
  • HLA B51 antigen, adult
  • Article
  • Behcet disease
  • best corrected visual acuity
  • cohort analysis
  • disease duration
  • drug dose increase
  • drug response
  • drug safety
  • drug use
  • drug withdrawal
  • female
  • follow up
  • human
  • major clinical study
  • male
  • monotherapy
  • onset age
  • pneumonia
  • priority journal
  • rash
  • relapse
  • retina vasculitis
  • retrospective study
  • survival rate
  • urticaria
  • uveitis

Cite this

Cumulative retention rate of adalimumab in patients with Behçet's disease-related uveitis: A four-year follow-up study. / Fabiani, C.; Sota, J.; Vitale, A.; Rigante, D.; Emmi, G.; Vannozzi, L.; Bacherini, D.; Lopalco, G.; Guerriero, S.; Gentileschi, S.; Capozzoli, M.; Franceschini, R.; Frediani, B.; Galeazzi, M.; Iannone, F.; Tosi, G.M.; Cantarini, L.

In: British Journal of Ophthalmology, Vol. 102, No. 5, 2018, p. 637-641.

Research output: Contribution to journalArticle

Fabiani, C, Sota, J, Vitale, A, Rigante, D, Emmi, G, Vannozzi, L, Bacherini, D, Lopalco, G, Guerriero, S, Gentileschi, S, Capozzoli, M, Franceschini, R, Frediani, B, Galeazzi, M, Iannone, F, Tosi, GM & Cantarini, L 2018, 'Cumulative retention rate of adalimumab in patients with Behçet's disease-related uveitis: A four-year follow-up study', British Journal of Ophthalmology, vol. 102, no. 5, pp. 637-641. https://doi.org/10.1136/bjophthalmol-2017-310733
Fabiani, C. ; Sota, J. ; Vitale, A. ; Rigante, D. ; Emmi, G. ; Vannozzi, L. ; Bacherini, D. ; Lopalco, G. ; Guerriero, S. ; Gentileschi, S. ; Capozzoli, M. ; Franceschini, R. ; Frediani, B. ; Galeazzi, M. ; Iannone, F. ; Tosi, G.M. ; Cantarini, L. / Cumulative retention rate of adalimumab in patients with Behçet's disease-related uveitis: A four-year follow-up study. In: British Journal of Ophthalmology. 2018 ; Vol. 102, No. 5. pp. 637-641.
@article{52897da10580441281cbeaa50dd58f59,
title = "Cumulative retention rate of adalimumab in patients with Beh{\cc}et's disease-related uveitis: A four-year follow-up study",
abstract = "Background/aims Adalimumab (ADA) has been shown to be an effective treatment for Beh{\cc}et's disease (BD)-related uveitis. We aimed at evaluating the cumulative retention rate of ADA during a 48-month follow-up period in patients with BD-related uveitis, the impact of a concomitant use of disease modifying anti-rheumatic drugs (DMARDs) on ADA retention rate, and differences according to the various lines of biologic therapy (ie, first- vs second-line or more). Predictive factors of response to ADA were also investigated. Methods We enrolled patients diagnosed with BD-related uveitis and treated with ADA between January 2009 and December 2016. Cumulative survival rates were studied using the Kaplan-Meier plot, while the log-rank (Mantel-Cox) test was used to compare survival curves. Statistical analysis was performed to identify differences according to the response to ADA. Results 54 consecutive patients (82 eyes) were eligible for analysis. The drug retention rate at 12- and 48-month follow-up was 76.9{\%} and 63.5{\%}, respectively. No statistically significant differences were identified according to the use of concomitant DMARDs (p=0.27) and to the different lines of ADA treatment (p=0.37). No significant differences were found between patients continuing and discontinuing ADA in terms of age (p=0.24), age at BD onset (p=0.81), age at uveitis onset (p=0.56), overall BD duration (p=0.055), uveitis duration (p=0.46), human leucocyte antigen-B51 positivity (p=0.51), and gender (p=0.47). Conclusions ADA retention rate in BD-related uveitis is excellent and is not affected by the concomitant use of DMARDs or by the different lines of biological therapy. Negative prognostic factors for BD uveitis do not impact ADA efficacy. {\circledC} Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved.",
keywords = "adalimumab, dexamethasone, disease modifying antirheumatic drug, HLA B51 antigen, adult, Article, Behcet disease, best corrected visual acuity, cohort analysis, disease duration, drug dose increase, drug response, drug safety, drug use, drug withdrawal, female, follow up, human, major clinical study, male, monotherapy, onset age, pneumonia, priority journal, rash, relapse, retina vasculitis, retrospective study, survival rate, urticaria, uveitis",
author = "C. Fabiani and J. Sota and A. Vitale and D. Rigante and G. Emmi and L. Vannozzi and D. Bacherini and G. Lopalco and S. Guerriero and S. Gentileschi and M. Capozzoli and R. Franceschini and B. Frediani and M. Galeazzi and F. Iannone and G.M. Tosi and L. Cantarini",
note = "cited By 8",
year = "2018",
doi = "10.1136/bjophthalmol-2017-310733",
language = "English",
volume = "102",
pages = "637--641",
journal = "British Journal of Ophthalmology",
issn = "0007-1161",
publisher = "BMJ Publishing Group",
number = "5",

}

TY - JOUR

T1 - Cumulative retention rate of adalimumab in patients with Behçet's disease-related uveitis: A four-year follow-up study

AU - Fabiani, C.

AU - Sota, J.

AU - Vitale, A.

AU - Rigante, D.

AU - Emmi, G.

AU - Vannozzi, L.

AU - Bacherini, D.

AU - Lopalco, G.

AU - Guerriero, S.

AU - Gentileschi, S.

AU - Capozzoli, M.

AU - Franceschini, R.

AU - Frediani, B.

AU - Galeazzi, M.

AU - Iannone, F.

AU - Tosi, G.M.

AU - Cantarini, L.

N1 - cited By 8

PY - 2018

Y1 - 2018

N2 - Background/aims Adalimumab (ADA) has been shown to be an effective treatment for Behçet's disease (BD)-related uveitis. We aimed at evaluating the cumulative retention rate of ADA during a 48-month follow-up period in patients with BD-related uveitis, the impact of a concomitant use of disease modifying anti-rheumatic drugs (DMARDs) on ADA retention rate, and differences according to the various lines of biologic therapy (ie, first- vs second-line or more). Predictive factors of response to ADA were also investigated. Methods We enrolled patients diagnosed with BD-related uveitis and treated with ADA between January 2009 and December 2016. Cumulative survival rates were studied using the Kaplan-Meier plot, while the log-rank (Mantel-Cox) test was used to compare survival curves. Statistical analysis was performed to identify differences according to the response to ADA. Results 54 consecutive patients (82 eyes) were eligible for analysis. The drug retention rate at 12- and 48-month follow-up was 76.9% and 63.5%, respectively. No statistically significant differences were identified according to the use of concomitant DMARDs (p=0.27) and to the different lines of ADA treatment (p=0.37). No significant differences were found between patients continuing and discontinuing ADA in terms of age (p=0.24), age at BD onset (p=0.81), age at uveitis onset (p=0.56), overall BD duration (p=0.055), uveitis duration (p=0.46), human leucocyte antigen-B51 positivity (p=0.51), and gender (p=0.47). Conclusions ADA retention rate in BD-related uveitis is excellent and is not affected by the concomitant use of DMARDs or by the different lines of biological therapy. Negative prognostic factors for BD uveitis do not impact ADA efficacy. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved.

AB - Background/aims Adalimumab (ADA) has been shown to be an effective treatment for Behçet's disease (BD)-related uveitis. We aimed at evaluating the cumulative retention rate of ADA during a 48-month follow-up period in patients with BD-related uveitis, the impact of a concomitant use of disease modifying anti-rheumatic drugs (DMARDs) on ADA retention rate, and differences according to the various lines of biologic therapy (ie, first- vs second-line or more). Predictive factors of response to ADA were also investigated. Methods We enrolled patients diagnosed with BD-related uveitis and treated with ADA between January 2009 and December 2016. Cumulative survival rates were studied using the Kaplan-Meier plot, while the log-rank (Mantel-Cox) test was used to compare survival curves. Statistical analysis was performed to identify differences according to the response to ADA. Results 54 consecutive patients (82 eyes) were eligible for analysis. The drug retention rate at 12- and 48-month follow-up was 76.9% and 63.5%, respectively. No statistically significant differences were identified according to the use of concomitant DMARDs (p=0.27) and to the different lines of ADA treatment (p=0.37). No significant differences were found between patients continuing and discontinuing ADA in terms of age (p=0.24), age at BD onset (p=0.81), age at uveitis onset (p=0.56), overall BD duration (p=0.055), uveitis duration (p=0.46), human leucocyte antigen-B51 positivity (p=0.51), and gender (p=0.47). Conclusions ADA retention rate in BD-related uveitis is excellent and is not affected by the concomitant use of DMARDs or by the different lines of biological therapy. Negative prognostic factors for BD uveitis do not impact ADA efficacy. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved.

KW - adalimumab

KW - dexamethasone

KW - disease modifying antirheumatic drug

KW - HLA B51 antigen, adult

KW - Article

KW - Behcet disease

KW - best corrected visual acuity

KW - cohort analysis

KW - disease duration

KW - drug dose increase

KW - drug response

KW - drug safety

KW - drug use

KW - drug withdrawal

KW - female

KW - follow up

KW - human

KW - major clinical study

KW - male

KW - monotherapy

KW - onset age

KW - pneumonia

KW - priority journal

KW - rash

KW - relapse

KW - retina vasculitis

KW - retrospective study

KW - survival rate

KW - urticaria

KW - uveitis

U2 - 10.1136/bjophthalmol-2017-310733

DO - 10.1136/bjophthalmol-2017-310733

M3 - Article

VL - 102

SP - 637

EP - 641

JO - British Journal of Ophthalmology

JF - British Journal of Ophthalmology

SN - 0007-1161

IS - 5

ER -